Literature DB >> 31097985

Treatment of Prostate Cancers and Kennedy's Disease by PROTAC-Androgen Receptor Degradation.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 31097985      PMCID： PMC6512008          DOI： 10.1021/acsmedchemlett.9b00115

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.

Authors:  Philipp Ottis; Craig M Crews
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

Review 2.  Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Authors:  Ian Churcher
Journal:  J Med Chem       Date:  2017-12-19       Impact factor: 7.446

Review 3.  Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.

Authors:  Gopinath Lakshmana; Aria Baniahmad
Journal:  Int J Cancer       Date:  2018-11-04       Impact factor: 7.396

Review 4.  Androgen receptor and soy isoflavones in prostate cancer.

Authors:  Monika Kmetová Sivoňová; Peter Kaplán; Zuzana Tatarková; Lucia Lichardusová; Róbert Dušenka; Jana Jurečeková
Journal:  Mol Clin Oncol       Date:  2018-12-11
  4 in total
  3 in total

1.  Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Authors:  Xin Han; Lijie Zhao; Weiguo Xiang; Chong Qin; Bukeyan Miao; Donna McEachern; Yu Wang; Hoda Metwally; Lu Wang; Aleksas Matvekas; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2021-08-25       Impact factor: 7.446

Review 2.  Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.

Authors:  Matthew R Burke; Alexis R Smith; Guangrong Zheng
Journal:  Front Cell Dev Biol       Date:  2022-04-25

3.  MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.

Authors:  Li-Zhe Xu; Jin-Zhuo Ning; Yuan Ruan; Fan Cheng
Journal:  J Clin Lab Anal       Date:  2022-03-18       Impact factor: 2.352
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.